272 related articles for article (PubMed ID: 9778079)
1. Influence of risk factors on peripheral and cerebrovascular disease in men with coronary artery disease, low high-density lipoprotein cholesterol levels, and desirable low-density lipoprotein cholesterol levels. HIT Investigators. Department of Veterans Affairs HDL Intervention Trial.
Papademetriou V; Narayan P; Rubins H; Collins D; Robins S
Am Heart J; 1998 Oct; 136(4 Pt 1):734-40. PubMed ID: 9778079
[TBL] [Abstract][Full Text] [Related]
2. Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group.
Wilt TJ; Rubins HB; Collins D; O'Connor TZ; Rutan GH; Robins SJ
Arch Intern Med; 1996 Jun; 156(11):1181-8. PubMed ID: 8639012
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol.
Rubins HB; Robins SJ; Iwane MK; Boden WE; Elam MB; Fye CL; Gordon DJ; Schaefer EJ; Schectman G; Wittes JT
Am J Cardiol; 1993 Jan; 71(1):45-52. PubMed ID: 8420235
[TBL] [Abstract][Full Text] [Related]
4. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
[TBL] [Abstract][Full Text] [Related]
5. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial.
Robins SJ; Collins D; Wittes JT; Papademetriou V; Deedwania PC; Schaefer EJ; McNamara JR; Kashyap ML; Hershman JM; Wexler LF; Rubins HB;
JAMA; 2001 Mar; 285(12):1585-91. PubMed ID: 11268266
[TBL] [Abstract][Full Text] [Related]
6. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
Rubins HB; Robins SJ; Collins D; Fye CL; Anderson JW; Elam MB; Faas FH; Linares E; Schaefer EJ; Schectman G; Wilt TJ; Wittes J
N Engl J Med; 1999 Aug; 341(6):410-8. PubMed ID: 10438259
[TBL] [Abstract][Full Text] [Related]
7. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.
J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296
[TBL] [Abstract][Full Text] [Related]
8. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial.
Boden WE
Am J Cardiol; 2000 Dec; 86(12A):19L-22L. PubMed ID: 11374850
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial.
Nyman JA; Martinson MS; Nelson D; Nugent S; Collins D; Wittes J; Fye CL; Wilt TJ; Robins SJ; Bloomfield Rubins H;
Arch Intern Med; 2002 Jan; 162(2):177-82. PubMed ID: 11802751
[TBL] [Abstract][Full Text] [Related]
10. Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).
Bloomfield Rubins H; Davenport J; Babikian V; Brass LM; Collins D; Wexler L; Wagner S; Papademetriou V; Rutan G; Robins SJ;
Circulation; 2001 Jun; 103(23):2828-33. PubMed ID: 11401940
[TBL] [Abstract][Full Text] [Related]
11. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).
Rubins HB; Robins SJ; Collins D; Nelson DB; Elam MB; Schaefer EJ; Faas FH; Anderson JW
Arch Intern Med; 2002 Dec 9-23; 162(22):2597-604. PubMed ID: 12456232
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
13. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM
Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157
[TBL] [Abstract][Full Text] [Related]
14. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol and coronary heart disease in Scotland.
Hargreaves AD; Logan RL; Thomson M; Elton RA; Oliver MF; Riemersma RA
BMJ; 1991 Sep; 303(6804):678-81. PubMed ID: 1912914
[TBL] [Abstract][Full Text] [Related]
15. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Veterans Affairs Cooperative Studies Program High-Density Lipoprotein Intervention Trial Study Group.
Rubins HB; Robins SJ; Collins D
Am J Cardiol; 1996 Sep; 78(5):572-5. PubMed ID: 8806347
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population. Canadian Heart Health Surveys Research Group.
Connelly PW; Petrasovits A; Stachenko S; MacLean DR; Little JA; Chockalingam A
Can J Cardiol; 1999 Apr; 15(4):428-33. PubMed ID: 10322252
[TBL] [Abstract][Full Text] [Related]
17. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
[TBL] [Abstract][Full Text] [Related]
18. [The characteristics of high density lipoprotein cholesterol and the relationship between high density lipoprotein cholesterol and the severity of coronary artery lesions in young men with acute myocardial infarction].
Li Z; Tao Y; Huang J; Wang Q; Zhang DH; Wu XY
Zhonghua Yi Xue Za Zhi; 2013 May; 93(19):1458-62. PubMed ID: 24029567
[TBL] [Abstract][Full Text] [Related]
19. Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, Triglycerides, and Apolipoprotein B and Cardiovascular Risk in Patients With Manifest Arterial Disease.
van den Berg MJ; van der Graaf Y; de Borst GJ; Kappelle LJ; Nathoe HM; Visseren FLJ;
Am J Cardiol; 2016 Sep; 118(6):804-810. PubMed ID: 27471056
[TBL] [Abstract][Full Text] [Related]
20. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease.
Tonelli M; Collins D; Robins S; Bloomfield H; Curhan GC
Am J Kidney Dis; 2004 Nov; 44(5):832-9. PubMed ID: 15492949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
